» Articles » PMID: 37256879

Trends in Low-density Lipoprotein Cholesterol Goal Achievement and Changes in Lipid-lowering Therapy After Incident Atherosclerotic Cardiovascular Disease: Danish Cohort Study

Overview
Journal PLoS One
Date 2023 May 31
PMID 37256879
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We aimed to investigate trends in low-density lipoprotein cholesterol (LDL-C) goal achievement (LDL-C<1.8 mmol/L, equivalent to 70 mg/dL), initiation of lipid-lowering therapy (LLT) and changes in LLT intensity in individuals with atherosclerotic cardiovascular disease (ASCVD) at very high risk of recurrent cardiovascular disease.

Methods: A cohort study design was used including individuals with incident ASCVD and LDL-C≥1.8 mmol/L in 2010-2015. Data were obtained from national, population-based registers (patient, prescription, income, and laboratory).

Results: We included 11,997 individuals. Acute myocardial infarction, ischemic stroke and stable angina pectoris accounted for 79.6% of the qualifying ASCVD events. At inclusion, 37.2% were in LLT. Mean LDL-C before or during ASCVD hospitalization was 3.1 mmol/L (120 mg/dL). LDL-C goal achievement increased within the first two years after inclusion from 40.5% to 50.6%. LLT initiation within the first 90 days increased from 48.6% to 56.0%. Initiation of intensive LLT increased from 9.6% to 32.8%. The largest change in LLT intensity was seen in the period 180 days before to 90 days after discharge with 2.2% in 2010 to 12.1% in 2015.

Conclusion: LDL-C goal achievement within the first 2 years after inclusion increased from 40.5% in 2010 to 50.6% in 2015. LLT initiation within the first year after inclusion increased, especially for intensive LLT, although only one third initiated intensive LLT in 2015. Despite trends show improvements in LDL-C goal achievement, 49.4% of individuals at very high risk of a CV event did not achieve the LDL-C goal within 2 years after ASCVD hospitalization.

Citing Articles

Applicability of Artificial Intelligence in the Field of Clinical Lipidology: A Narrative Review.

Masson W, Corral P, Nogueira J, Lavalle-Cobo A J Lipid Atheroscler. 2024; 13(2):111-121.

PMID: 38826186 PMC: 11140245. DOI: 10.12997/jla.2024.13.2.111.

References
1.
Lamprecht Jr D, Shaw P, King J, Hogan K, Olson K . Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. J Clin Lipidol. 2018; 12(4):999-1007. DOI: 10.1016/j.jacl.2018.04.007. View

2.
Fox K, Tai M, Kostev K, Hatz M, Qian Y, Laufs U . Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2017; 107(5):380-388. PMC: 5913378. DOI: 10.1007/s00392-017-1193-z. View

3.
Kuiper J, Sanchez R, Houben E, Heintjes E, Penning-van Beest F, Khan I . Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clin Ther. 2017; 39(4):819-827.e1. DOI: 10.1016/j.clinthera.2017.03.001. View

4.
Rodriguez F, Olufade T, Heithoff K, Friedman H, Navaratnam P, Foody J . Frequency of high-risk patients not receiving high-potency statin (from a large managed care database). Am J Cardiol. 2014; 115(2):190-5. DOI: 10.1016/j.amjcard.2014.10.021. View

5.
Laslett L, Alagona Jr P, Clark 3rd B, Drozda Jr J, Saldivar F, Wilson S . The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012; 60(25 Suppl):S1-49. DOI: 10.1016/j.jacc.2012.11.002. View